We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site

IsoPlexis Proteomic Product Suite for CAR-T Therapy

Learn how IsoPlexis’ Functional Proteomics reveals unique secretomic signatures and insights into CAR-T therapy.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

Overcoming challenges in CAR-T therapy and antigen escape in Multiple Myeloma
Comparing subtle gene edits in NK cell therapies
Precision analytics in automated CAR-T manufacturing with single-cell proteomics
Preinfusion biomarkers for predicting clinical outcome in CAR-T cell treatment
A Deeper Look

More about this

Overcoming Challenges in CAR-T Therapy

Cell therapy relies on immune cells from patients or healthy donors, and in the case of allogeneic therapies, development and production are more complicated.

To ensure that these cell products are potent and effective, knowing how to engineer potency and durability throughout the development and bioprocessing stages is crucial.

Download this App Note to learn how IsoPlexis can help you achieve this faster.

Get the